EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY trial)
Acronym
EMPATHY
Project Title
EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY trial)
Financing Institution
Medical Research Agency
Medical Research Agency
Lead
Prof. dr hab. Marek Postuła Prof. dr hab. Jolanta Siller-Matula
Subject
EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY trial)
Project Objective
The aim of the project is the assessment of:
1) influence of SGLT-2 inhibitors (Empagliflozin and Dapagliflozin) on primary and secondary clinical end-points in patients with acute/unstable heart failure (AHF);
2) influence of SGLT-2 inhibitors on heart rate;
3) influence of SGLT-2 inhibitors on biomarkers and circulating micro RNA (miRNA) and microbiome metabolites
4) proposing a risk prognosis scale in order to closely monitor the course of AHF and its treatment with SGLT-2 inhibitors based on selected miRNA and biomarkers related to molecular trails related to the course of the disease